Advagene Biopharma Co (ROCO:6709) ROCE %: -40.61% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6709 Advagene Biopharma Co Ltd ROCO:6709
36 GF Score
Price NT$24.55
! 2 Warning Signs
View Full Analysis

What is Advagene Biopharma Co ROCE %?

Advagene Biopharma Co ROCO:6709 +0.41% 36 ROCE % is -40.61% as of Dec. 2025. GuruFocus rates ROCO:6709 with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Advagene Biopharma Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -40.61%.

Advagene Biopharma Co  (ROCO:6709) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Advagene Biopharma Co ROCE % Related Terms

Advagene Biopharma Co ROCE % Historical Data

* Premium members only.

The historical data trend for Advagene Biopharma Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advagene Biopharma Co ROCE % Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.30 -61.52 -67.61 -37.95 -35.85

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.80 -49.39 -44.70 -31.71 -40.61
ROCO:6709
36GF Score
Advagene Biopharma Co Ltd ROCO:6709
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advagene Biopharma Co ROCE % Calculation

Advagene Biopharma Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-68.114/( ( (232.208 - 7.107) + (166.513 - 11.613) )/ 2 )
=-68.114/( (225.101+154.9)/ 2 )
=-68.114/190.0005
=-35.85 %

Advagene Biopharma Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-70.246/( ( (197.256 - 6.189) + (166.513 - 11.613) )/ 2 )
=-70.246/( ( 191.067 + 154.9 )/ 2 )
=-70.246/172.9835
=-40.61 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -40.61% mean?
Advagene Biopharma Co (ROCO:6709) has a ROCE % of -40.61% as of Dec. 2025.
Is Advagene Biopharma Co's ROCE % too high?
Advagene Biopharma Co's current ROCE % is -40.61%. Overall, Advagene Biopharma Co has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Advagene Biopharma Co's ROCE % compare to VRTX and REGN?
Advagene Biopharma Co's ROCE % of -40.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Advagene Biopharma Co's current ROCE % is -40.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advagene Biopharma Co stock overvalued right now?
Advagene Biopharma Co (ROCO:6709) has a current ROCE % of -40.61%. The current ROCE % is -40.61%. Advagene Biopharma Co's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Advagene Biopharma Co (ROCO:6709), the current ROCE % is -40.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advagene Biopharma Co Business Description

Address Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based biotechnology company. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray seasonal flu vaccine, nasal spray COVID-19 vaccine, Immunotherapy for COVID-19, Respiratory Allergy Immunotherapy - Allergic Rhinitis and Asthma ,and other vaccines.
36GF Score

Get the complete analysis for ROCO:6709

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.55
Price